How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 11 Jul | 18 Jul | 25 Jul | 24 Aug | 28 Aug | 04 Sep | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 69.0 | 68.3 | 68.3 | 68.4 | 68.4 | 68.4 | -0.6 |
| Healthcare | 29.3 | 30.4 | 30.4 | 29.3 | 29.3 | 29.3 | +0.0 |
| Chemicals | 1.1 | 1.1 | 1.1 | 1.0 | 1.0 | 1.0 | -0.1 |
| Unclassified | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.0 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 11.06% | 7 | 8 | 7 | 8 | 5 | — | +1.5% |
| DIVISLAB | Pharma | 8.71% | 9 | 8 | 1 | 4 | 1 | — | +38.4% |
| TORNTPHARM | Pharma | 7.47% | 7 | 8 | 5 | 4 | 1 | — | +7.0% |
| APOLLOHOSP | Healthcare | 5.94% | 9 | 5 | 5 | 2 | 2 | — | +0.4% |
| GLENMARK | Pharma | 5.53% | 10 | 9 | 9 | 4 | 3 | — | +8.2% |
| LAURUSLABS | Pharma | 5.13% | 9 | 9 | 3 | 3 | 1 | — | +29.2% |
| AUROPHARMA | Pharma | 3.82% | 8 | 3 | 10 | 6 | 7 | — | +9.9% |
| ALKEM | Pharma | 3.56% | 3 | 8 | 7 | 6 | 8 | — | -6.6% |
| FORTIS | Healthcare | 3.55% | 4 | 8 | 5 | 5 | 6 | — | -12.4% |
| KIMS | Healthcare | 3.48% | 4 | 3 | 6 | 10 | 2 | — | -9.0% |
| DRREDDY | Pharma | 3.46% | 2 | 2 | 6 | 10 | 9 | — | -14.7% |
| LUPIN | Pharma | 3.27% | 3 | 10 | 10 | 7 | 9 | — | -11.1% |
| ONESOURCE | Healthcare | 3.23% | 3 | 1 | 6 | 7 | 8 | — | -15.1% |
| SAILIFE | Healthcare | 3.17% | 9 | 10 | 5 | 9 | 1 | Leader | +27.8% |
| ASTERDM | Healthcare | 3.14% | 6 | 2 | 9 | 4 | 2 | — | -0.6% |
| IPCALAB | Pharma | 3.13% | 9 | 5 | 1 | 3 | 4 | — | +14.3% |
| CIPLA | Pharma | 3.03% | 4 | 3 | 6 | 4 | 7 | — | -3.9% |
| ERIS | Pharma | 2.82% | 3 | 8 | 4 | 9 | 8 | — | -7.4% |
| LALPATHLAB | Healthcare | 2.81% | 7 | 8 | 7 | 5 | 3 | — | +18.6% |
| MAXHEALTH | Healthcare | 2.81% | 1 | 9 | 6 | 5 | 6 | — | -6.0% |
| GLAND | Pharma | 2.11% | 10 | 7 | 5 | 4 | 4 | Leader | +27.9% |
| BIOCON | Pharma | 2.08% | 4 | 1 | 10 | 2 | 7 | — | -8.8% |
| MANKIND | Pharma | 2.04% | 4 | 8 | 9 | 3 | 5 | — | -6.1% |
| NH | Healthcare | 1.19% | 5 | 8 | 7 | 10 | 4 | — | -4.9% |
| ANTHEM | Pharma | 1.15% | 10 | 10 | 6 | 3 | 1 | Leader | +16.3% |
| NEOGEN | Chemicals | 0.61% | 9 | 2 | 8 | 6 | 1 | — | +11.1% |
| DEEPAKNTR | Chemicals | 0.44% | 6 | 1 | 1 | 3 | 6 | — | -5.8% |
Performance · 5.0y
Over the last 5.0 years ₹100 in the fund grew to ₹195 (+95%), vs ₹156 for Nifty 500 (+56%) and ₹137 for Nifty 50 (+37%). Its relative-strength line ended at 143 vs Nifty 50 and 125 vs Nifty 500 — above 100, sustained outperformance.